https://www.selleckchem.com/pr....oducts/SB-525334.htm
With notable risk of recurrence of FSGS in kidney transplants leading to allograft failure, the use of ofatumumab and eplerenone in conjunction should be considered for management to induce remission. With notable risk of recurrence of FSGS in kidney transplants leading to allograft failure, the use of ofatumumab and eplerenone in conjunction should be considered for management to induce remission. The number of pulmonary arterial hypertension (PAH) patients with comorbidities is increasing and there are limited data on response to PA
Like
Comment
Share
